Anemia Management in Pregnancy

Diagnosis and Screening

Screen for anemia at the first prenatal visit and monitor throughout pregnancy, using pregnancy-specific anemia criteria when interpreting hemoglobin values, as recommended by the Centers for Disease Control and Prevention (CDC) 1
Mild microcytic anemia (MCV <80 fL) that does not respond adequately to iron supplementation should be further evaluated, as reported by the CDC 1
Thalassemia minor can be screened by evaluating mean cell volume (MCV), which will be <80 fL in thalassemia carriers, and hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) can confirm the diagnosis, as recommended by the American College of Medical Genetics and the CDC 2, 1

Pregnant women with alpha thalassemia minor without iron deficiency should receive routine iron supplementation (30 mg/day), while those with concurrent iron deficiency may require higher doses (60-120 mg/day), as suggested by the CDC 1
Monitor response to iron therapy; lack of response after 4 weeks despite compliance suggests the anemia is primarily due to thalassemia rather than iron deficiency, according to the CDC 1

If anemia does not respond to iron therapy after 4 weeks, further evaluate with MCV, RDW, and serum ferritin concentration, as recommended by the CDC 1
Elevated RDW (>14.0%) suggests iron deficiency anemia, whereas normal RDW (≤14.0%) typically indicates thalassemia minor, according to the CDC guidelines 1
Molecular genetic testing, including PCR-based techniques, gap-PCR, DNA sequencing, and reverse dot blot hybridization, can identify specific mutations in the globin genes, essential for definitive diagnosis and classification of thalassemia, as noted by 3

The American Society of Hematology recommends initiating iron chelation when serum ferritin exceeds 1000 ng/mL to prevent organ damage, with available options including:
Therapy Dosage Administration
Deferasirox Oral
Deferiprone 75 mg/kg/day Oral, 3 divided doses
Deferoxamine 40-50 mg/kg/day Subcutaneous or intravenous infusion
Combination therapy with deferiprone and deferoxamine shows superior efficacy for severe iron overload, as recommended by the International Society of Hematology and the American Heart Association 5, 4

Therapy	Dosage	Administration
Deferasirox		Oral
Deferiprone	75 mg/kg/day	Oral, 3 divided doses
Deferoxamine	40-50 mg/kg/day	Subcutaneous or intravenous infusion

The American College of Cardiology recommends cardiac T2* MRI for early detection of cardiac iron overload and regular echocardiography to assess cardiac function, with heart failure in thalassemia being a medical emergency requiring immediate specialist care, as recommended by the American College of Cardiology and the American Heart Association 4, 5
Cardiac T2 MRI is essential for early detection of cardiac iron overload, with severe cardiac iron indicated by T2 <10 ms, moderate cardiac iron by T2 10-20 ms, and normal by T2 >20 ms, as recommended by the American Heart Association 5, 4
Ferritin levels >2500 μg/L indicate increased risk of cardiac complications, but risk increases even at levels of 1000 μg/L, as noted by the European Society of Cardiology and the American Heart Association 5, 4
The American Association for the Study of Liver Diseases recommends liver iron concentration (LIC) assessment and ultrasound analysis every 6-12 months in patients with cirrhosis, with screening for hepatitis C and appropriate management, as recommended by the American Association for the Study of Liver Diseases and the American College of Gastroenterology 4, 5

The American Society of Hematology recommends hematopoietic stem cell transplantation (HSCT) as the only definitive cure available, with most successful outcomes when performed early in life before iron overload complications develop, as recommended by the American Society of Hematology and the International Bone Marrow Transplant Registry 4, 5
Emerging therapies include gene therapy and stimulation of fetal hemoglobin production, as noted by the National Institute of Diabetes and Digestive and Kidney Diseases 4
The American Society of Hematology recommends screening for hepatitis C and appropriate management in patients with thalassemia, with combination therapy with Peg-interferon plus ribavirin for patients with HCV chronic hepatitis or compensated cirrhosis, as recommended by the American Society of Hematology and the American Association for the Study of Liver Diseases 4, 5

The American College of Medical Genetics recommends genetic counseling for families with thalassemia history, with targeted screening for individuals with ancestry from Mediterranean, Middle East, Africa, and Southeast Asia, as recommended by the American College of Medical Genetics and the National Institutes of Health 4, 5
Genetic counseling is recommended for families with a history of thalassemia, as well as prenatal diagnosis through amniocentesis or chorionic villus sampling with DNA analysis, to identify at-risk individuals and prevent complications, as recommended by the National Institutes of Health, the American College of Obstetricians and Gynecologists, and the Centers for Disease Control and Prevention 5, 2, 4